Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLNNASDAQ:BYSINASDAQ:NLTXNASDAQ:RAIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/ABYSIBeyondSpring$2.51+2.4%$1.96$0.98▼$3.44$98.78M0.0732,306 shs17,039 shsNLTXNeoleukin Therapeutics$17.20-0.1%$17.03$2.03▼$14.36$161.65M1.1150,104 shs238,965 shsRAINRain Enhancement Technologies Holdco$2.87$1.21$0.82▼$11.32$21.77M-0.2212,229 shs9,407 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%-75.96%BYSIBeyondSpring-10.58%-27.94%+41.70%+64.43%-1.41%NLTXNeoleukin Therapeutics-3.04%-9.23%-0.35%+23.35%-44.47%RAINRain Enhancement Technologies Holdco-0.35%-12.31%-31.59%+48.70%+137.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/ABYSIBeyondSpring 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ARAINRain Enhancement Technologies Holdco 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09BYSIBeyondSpring$1.75M57.83N/AN/A($0.37) per share-6.78NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/A($0.96) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/A∞N/AN/A-8,454.87%-121.60%N/ABYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ARAINRain Enhancement Technologies Holdco-$4.53MN/A0.00∞N/AN/AN/A-43.86%N/ALatest BYSI, RAIN, NLTX, and ASLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RAINRain Enhancement Technologies HoldcoN/A-$0.20N/A-$0.20N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05BYSIBeyondSpringN/A2.492.49NLTXNeoleukin TherapeuticsN/A15.3315.33RAINRain Enhancement Technologies HoldcoN/A0.090.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%BYSIBeyondSpring40.29%NLTXNeoleukin Therapeutics52.37%RAINRain Enhancement Technologies Holdco25.79%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%BYSIBeyondSpring29.31%NLTXNeoleukin Therapeutics1.58%RAINRain Enhancement Technologies Holdco17.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataRAINRain Enhancement Technologies Holdco637.59 million6.27 millionNo DataBYSI, RAIN, NLTX, and ASLN HeadlinesRecent News About These CompaniesRiders brave the rain to ride for a cause during Cruise for CancerJune 9, 2025 | msn.com'AI Can Detect Cancer, But Bengaluru Still Can’t Handle Rain?' Investor's Viral Rant Sparks DebateMay 21, 2025 | msn.comThousands brave rainy weather for Race For Hope to fund brain cancer researchMay 9, 2025 | msn.comPart of Horn Island is up for sale, listed for $25MMay 9, 2025 | wlox.comW10-year-old cancer survivor rings bell, throws first pitch at Space Cowboys gameMay 3, 2025 | msn.comLead singer for popular U.K. rock band dies at 66May 1, 2025 | msn.comMike Peters Dies: The Alarm’s Frontman Was 66May 1, 2025 | msn.comThey Can’t Rain on Her ParadeApril 14, 2025 | capemaycountyherald.comCToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 7, 2025 | msn.comBrain cancer: Recognising tumour symptoms, risk factors and seeking treatmentNovember 24, 2024 | msn.comStars shine despite rain on Illinois’ Night of ChampionsNovember 15, 2024 | harnessracingupdate.comHUI researcher wins $10 million dollars to combat ovarian cancerNovember 14, 2024 | kwwl.comK'Smart freeway' to cut commute for thousands of Perth motoristsNovember 14, 2024 | 9news.com.au9Icy spots possible Wednesday morning as temperatures fall below freezingNovember 13, 2024 | atlantic.ctvnews.caANewfoundland man electrocuted by downed power line, two women injuredNovember 11, 2024 | msn.comKing Charles III and Kate attend remembrance events as both slowly return to dutyNovember 11, 2024 | msn.comPrince William describes family's ‘brutal’ year as wife and father faced cancer treatmentNovember 8, 2024 | msn.comThe Eras Tour kept me going during my breast cancer treatmentNovember 8, 2024 | theglobeandmail.comSheila Jackson Lee’s daughter to finish her mother’s term before former Houston mayor takes 18th Congressional DistrictNovember 7, 2024 | click2houston.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBYSI, RAIN, NLTX, and ASLN Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 06/24/2025ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.BeyondSpring NASDAQ:BYSI$2.51 +0.06 (+2.45%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.02 (+0.80%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Neoleukin Therapeutics NASDAQ:NLTX$17.20 -0.02 (-0.12%) As of 06/24/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Rain Enhancement Technologies Holdco NASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
